One analysis showed participant costs were substantially lower – 8% below an employer client's general adult population and ...

BERLIN & NEW YORK, October 21, 2025--(BUSINESS WIRE)--StratifAI, the AI precision oncology company behind the Polaris™ platform, today announced its selection for the Memorial Sloan Kettering (MSK) ...

Artificial intelligence is reshaping many fields, and its impact on healthcare grows by the day. Computational neuroscience, using mathematical and ...

Virtual screening methods fall broadly into two categories: ligand- and structure-based. Ligand-based virtual screening doesn’t require a target protein structure, Instead, it leverages known active ...

Breast cancer is the most commonly diagnosed form of cancer in the world among women, with more than 2.3 million cases a year ...

Artificial intelligence (AI) is rapidly transforming clinical trials by dramatically reducing timelines and costs, accelerating patient-centered drug development and creating more resilient and ...

Tulisokibart, an investigational anti-TL1A monoclonal antibody currently in Phase 3 trials for ulcerative colitis and Crohn’s disease, to be studied in hidradenitis suppurativa, radiographic axial ...

StratifAI, the AI precision oncology company behind the Polaris™ platform, today announced its selection for the Memorial Sloan Kettering (MSK) iHub Challenge 2025 Cohort program. This engagement will ...

Choose from one of two sub-specialties in our program: our adult track, or our child and family track (you may choose to specialize in pediatric psychology within the latter). You can complete either ...